PROGRAMMA PRELIMINARE

Con il patrocinio di

SIE - *Società Italiana di Ematologia*

Lucca, 15th-16th June 2016

IMT Institute for advanced studies
Piazza S. Francesco, 19

Wednesday, 15th june 2016

The Young Biomarkers Day		
10.00 - 10.30	Welcome	
	Director of IMT School for Advanced Studies Lucca	*P. Pietrini*
	Rector, University of Pisa	*M. M. Augello*
	General Director, University Hospital	*C. R. Tomassini*
	Director of Department of Clinical and Experimental Medicine	*M. Petrini*
	Director of Department of Laboratory Medicine	*R. Danesi*
	Chairmen: S. Galimberti & R. Danesi	
10.30 - 11.00	PGx data: clinical application in oncology	*R. van Schaik*
11.00 - 11.30	Pharmacokinetic modeling incorporating PGx data: clinical application in hematology	*A. Di Paolo*
11.30 - 12.00	Coffee break	
	Chairmen: M. Del Re & F. Massari	
12.00 - 12.30	Clinical trials for the study of biomarkers: from classical to innovative designs	*M. Di Maio*
12.30 - 13.00	Clinical trial design: how to validate circulating nucleic acids?	*S. Pilotto*
13.00 - 14.30	Lunch	
	Chairmen: M. Di Maio & C. Cremolini	
14.30 - 15.00	Clinical case I – CNAs in CRC	*C. Antoniotti*
15.00 - 15.30	Clinical case II – CNAs in NSCLC	*I. Petrini*
15.30 - 16.00	Clinical case III – CNAs in mBC	*M. Lambertini*
16.00 - 16.30	Coffee break	
	Incorporating PGx into clinical practice	
16.30 - 17.00	The role of the pharmacologist	*E. Dreussi*
17.00 - 17.30	The interest of the oncologist	*E. Vasile*

Thursday, 16th june 2016

Golden Helix Pharmacogenomics Day		
09.00 - 09.30	Welcome	*R. Danesi, G. Patrinos*
	Chairmen: F. Citterio & U. Boggi	
09.30 - 10.00	Pharmacogenomics in the era of Precision Medicine	*G. Patrinos*
10.00 - 10.30	How and when to monitor CNAs in transplantation	*R. van Schaik*
10.30 - 11.00	Clinical applications of CNAs in renal transplant	*D. A. Hesselink*
11.00 - 11.30	Coffee break	
	Chairmen: G. Fontanini & A. Falcone	
11.30 - 12.00	How and when to monitor CNAs in oncology	*R. Danesi*
12.30 - 12.30	Pros and cons of tissue vs CNAs	*A. Scarpa*
12.30 - 12.50	The future of Personalize Health Care: The Biotech experience	*A. Kiermaier/R. Scalamogna*
12.50 - 14.30	Lunch	
	Chairmen: R. Rosell & G. Masi	
14.30 - 15.00	Clinical applications of CNAs in NSCLC	*N. Karachaliou*
15.00 - 15.30	Clinical applications of CNAs in colorectal cancer	*C. Cremolini*
15.30 - 16.00	Clinical applications of CNAs in breast cancer	*I. Garcia-Murillas*
16.00 - 16.30	Coffee break	
	Chairmen: R. van Schaik & S. Galimberti	
16.30 - 17.00	Clinical applications of CNAs in prostate cancer	*G. Jenster*
17.00 - 17.30	Clinical applications of CNAs in haematologic malignancies	*S. Ferrero*
17.30 - 18.00	Are we ready for prime time use?	*G. Argilés Martínez*
18.00 - 18.30	Conclusions and quiz ECM	

Scientific Directors

Romano Danesi
George Patrinos
Marzia Del Re

Scientific Secretariat

Chiara Cremolini
Francesco Massari

Faculty

Guillem Argilés Martínez
Carlotta Antoniotti
Massimo Mario Augello
Ugo Boggi
Franco Citterio
Chiara Cremolini
Romano Danesi
Marzia Del Re
Massimo Di Maio
Antonello Di Paolo
Eva Dreussi
Alfredo Falcone
Simone Ferrero
Gabriella Fontanini
Sara Galimberti
Isaac Garcia-Murillas
Dennis Hesselink
Guido Jenster
Niki Karachaliou
Astrid Kiermaier
Matteo Lambertini
Gianluca Masi
Francesco Massari
George Patrinos
Iacopo Petrini
Mario Petrini
Pietro Pietrini
Sara Pilotto
Rafael Rosell
Roberto Scalamogna
Aldo Scarpa
Carlo Rinaldo Tomassini
Ron van Schaik
Enrico Vasile

Rationale YBD-GHF

The search for biomarkers is increasingly required in many disciplines: in cancer, to assess the response to treatment and risk of treatment-related toxicity, as well as in transplants to monitor the graft injury.Significant achievements have been made in our understanding and clinical application of pharmacogenetics in cancer of drug-metabolising enzymes in order to predict fluoropyrimidine- and irinotecan-related toxicities with the screening of DPYD and UGT genes, respectively.Circulating tumour DNA could represent a powerful diagnostic tool to help clinical decision making, as it is being used, at least for research purposes, to assess tumour heterogeneity, identify genetic determinants for targeted therapy, evaluate the response to treatment and assess the evolution of molecular resistance over time. Moreover, the field of solid organ transplantation has been seeing improved graft outcomes, with reduced rates of acute rejection due to the use of immunosuppressive drugs (tacrolimus, cyclosporine, MMF). However, the diagnostic tools available to monitor the transplant rejection are costly, have the danger of complications or are available too late for the patient. A new and innovative approach for detecting organ rejection makes use of plasma graft-derived cell free DNA in the recipient, arising from damaged cells when the transplanted donor organ is subject to rejection.

However, the choice of genetic markers and the implementation of new technologies in clinical practice should be discussed between the main stakeholders.

The Young Biomarkers Day and the Golden Helix Symposium on Circulating Nucleic Acids will address these important issues by involving young researchers and expert scientists, with the aim of discussing the appropriate use of technological platforms and molecular biomarkers in transplants and in solid tumours (i.e. colorectal, lung, breast cancer and melanoma), especially in the era of new therapeutic options (i.e. immunotherapy, monoclonal antibodies and new immunosoppressive drugs).

Informazioni ECM

- Data 15/05/2016 evento nr: 158540
- Crediti assegnati: 4,5
- Data 16/05/2016 evento nr: 158544
- Crediti assegnati: 4,5
- Evento accreditato per:
  - Professione: Medico Chirurgo (tutte le discipline), Biologo, Farmacista, Infermiere, Tecnico Sanitario Laboratorio Biomedico
- Obiettivo formatico: Contenuti tecnico-professionali (conoscenze e competenze) specifici di ciascuna professione, di ciascuna specializzazione e di ciascuna attività ultraspecialistica. Malattie rare
- Ai fini dell'acquisizione dei crediti formativi è necessaria la presenza effettiva per il 100% della durata complessiva dell'evento ed il superamento delle verifiche di apprendimento
- Il limite massimo dei crediti formativi ricondotti al triennio di riferimento acquisibili mediante reclutamento diretto è di 1/3

Provider ECM - 316

EUREKA
comunicazione e formazione

Via Ss. Annunziata, 187/C - 55100 Lucca (LU)
Tel. 0583 1550100 - Fax 0583 503022
segreteria@edukarea.it